In the past decade, AbbVie’s Humira and Amgen’s Enbrel tumor necrosis factor-alpha (TNF-α) inhibitors and Janssen’s interleukin (IL)-12/23 inhibitor Stelara have been leading the U.S. psoriasis biologics market. However, the recent wave of U.S. approvals for novel psoriasis agents—including Celgene’s Otezla, three IL-17 inhibitors, and two IL-23 inhibitors—is altering the market landscape. The oral agent Otezla has been successfully carving out a space in biologics-naive patients. The more-effective biologics, Novartis’s Cosentyx and Eli Lilly’s TaltzIL-17 inhibitors, are threatening the first-line dominance of TNF-α inhibitors, and Janssen’s IL-23 inhibitor Tremfya is likely to follow. With the recent entry of biosimilars and another IL-23 inhibitor in late-phase development, marketers of psoriasis therapies will learn how they can best overcome the formulary and uptake challenges facing current and emerging therapies in this increasingly competitive market.
- What are the current patient share leaders among psoriasis biologics/Otezla, and which psoriasis agents do physicians and payers perceive as performing best on specific clinical and market access factors?
- How do payers cover/anticipate covering biosimilar versions of infliximab (Pfizer’s Inflectra, Merck’s Renflexis) and adalimumab (Amgen’s Amgevita), and what are physicians’ expected prescribing behaviors of biosimilars?
- What are physician perceptions of emerging biologics, such as risankizumab, and how do payers anticipate covering these novel agents? How are recent entrants to the market faring in terms of payer coverage and restrictions?
- What pharmacoeconomic models and data do payers value for examining the cost and efficacy impact of novel psoriasis agents?
Access & Reimbursement provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.